- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05:26 | Impact Biomedical, Inc.: Impact Biomedical Inc. and Zoar Limited Announce SEC Declaration of Effectiveness of Form F-4 Registration Statement, Marking Major Milestone Toward Closing of Proposed Business Combination | 355 | ACCESS Newswire | Special meeting of Impact Biomedical stockholders to approve the proposed Business Combination scheduled for November 13, 2026, at 10:00 a.m. Eastern Standard TimeUpon closing, the combined company... ► Artikel lesen | |
| 09.10. | IMPACT BIOMEDICAL INC. - 8-K, Current Report | - | SEC Filings | ||
| IMPACT BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 16.09. | Impact Biomedical files F-4 for business combination | 2 | Investing.com | ||
| 16.09. | Fusion mit Zoar Labs: Impact Biomedical reicht F-4-Antrag ein | 2 | Investing.com Deutsch | ||
| 16.09. | DSS, Inc. Announces Form F-4 Filing in Connection with Impact Biomedical's Proposed Business Combination with Zoar Limited | 2 | GlobeNewswire (USA) | ||
| 16.09. | Impact BioMedical, Inc.: Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley's Limited) | 506 | GlobeNewswire (Europe) | HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (NYSE: IBO) (the "Company" or "Impact") announced that a Form F-4 registration statement (the "Registration Statement") was filed... ► Artikel lesen | |
| 15.09. | Impact Biomedical corrects merger exchange ratio, sets reverse stock split | 1 | Investing.com | ||
| 15.09. | Impact BioMedical, Inc. Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited) | 275 | GlobeNewswire (Europe) | HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Impact Biomedical Inc (NYSE: IBO) today announced that the Company's Board of Directors has approved a 1 for 12.62 reverse stock split of the Company's issued... ► Artikel lesen | |
| 11.09. | Impact BioMedical beschließt Aktienzusammenlegung im Verhältnis 1 zu 12,62 | 1 | Investing.com Deutsch | ||
| 11.09. | Impact BioMedical approves 1-for-12.62 reverse stock split | 1 | Investing.com | ||
| 07.08. | IMPACT BIOMEDICAL INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.05. | IMPACT BIOMEDICAL INC. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 03.04. | Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans | 297 | GlobeNewswire (Europe) | HOUSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO) announced that its annual report(10-K) for the fiscal year ending December 31, 2025, filed on March 11, 2026... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 8,540 | +0,47 % | Novavax erhält 125 Millionen - dann steigt Großaktionär aus | ||
| INOVIO PHARMACEUTICALS | 1,693 | -0,06 % | Aktien New York Ausblick: Erholungsversuch vor US-Zwischenwahlen | NEW YORK (dpa-AFX) - Nach den herben Verlusten vom Freitag und vor den am Dienstag anstehenden Zwischenwahlen in den USA dürften die US-Börsen am Montag einen Erholungsversuch starten. Im Anlegerfokus... ► Artikel lesen | |
| INFLARX | 1,479 | -6,21 % | InflaRx-Aktie +3,3 %: Neue Klinikchefin und Kidney-Week-Daten | ||
| INTELLIA THERAPEUTICS | 10,480 | +0,58 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026 | ||
| EDITAS MEDICINE | 2,360 | +3,06 % | Editas Medicine, Inc.: Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia | Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,317 | +2,92 % | 3 Datenpakete vor dem ersten Patienten: Wie NurExone ExoPTEN auf die Klinik vorbereitet | ||
| GERON | 0,822 | -1,11 % | XFRA GON: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILGERON CORP. (DEL.)... ► Artikel lesen | |
| IBIO | 0,723 | +2,12 % | iBio, Inc.: iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update | SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| IMMUNITYBIO | 7,130 | +0,56 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMATICS | 6,325 | +0,64 % | Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting | IMA402 PRAME bispecific continues to demonstrate encouraging anti-tumor activity in multiple indications, alongside a favorable safety profileIMA402 achieved a cORR of 32%, 12.5 months median DOR and... ► Artikel lesen | |
| MYRIAD GENETICS | 5,210 | -6,60 % | Labcorp To Buy Myriad Genetics' Prenatal Testing Business For $210 Mln | WASHINGTON (dpa-AFX) - Laboratory services provider LabCorp Holdings Inc. (LH) announced on Tuesday that it has agreed to acquire the Prenatal Health testing business of molecular diagnostics... ► Artikel lesen | |
| MANNKIND | 3,225 | 0,00 % | MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management | Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere- inhalation technologyMannKind to receive an equity interest and potential royalties... ► Artikel lesen | |
| GINKGO BIOWORKS | 8,320 | -5,41 % | Ginkgo Bioworks Holdings, Inc. - 8-K, Current Report | ||
| IMMUNIC | 6,694 | -2,82 % | EQS-News: Immunic AG: Immunic to Participate in Investor Conferences in November | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Investor Conferences in November
02.11.2026 / 12:30 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 7,180 | +0,42 % | Iovance Biotherapeutics Inc. - IOVA: weißer Rauch bei Lungenkrebs-Daten? | Intraday Trade? Rekordumsatz in Q2 bei Iovance Biotherapeutics. Lifileucel-Therapie mit Mega-Marktpotenzial! Vorbörsliches Gap Up! Iovance Biotherapeutics (IOVA) - US4622601007 Rückblick Nach einer... ► Artikel lesen |
Das Unternehmen IMPACT BIOMEDICAL INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 4,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMPACT BIOMEDICAL INC finden Sie auf Wallstreet Online.